Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health...
14 insider sale filings on record · latest filing 2026-09-29.
No open-market insider purchases (SEC Form 4 code P) on record for DFTX.